The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
HDAC6 as privileged target in drug discovery: A perspective
Abstract
HDAC6, a class II b HDAC isoenzyme, stands unique in its structural and physiological functions. Besides histone modification, largely due to its cytoplasmic localization, HDAC6 also targets several non-histone proteins including Hsp90, α-tubulin, cortactin, HSF1, etc. Thus, it is one of the key regulators of different physiological and pathological disease conditions. HDAC6 is involved in different signaling pathways associated with several neurological disorders, various cancers at early and advanced stage, rare diseases and immunological conditions. Thus, targeting HDAC6 has been found to be effective for various therapeutic purposes in recent years. Though several HDAC6 inhibitors (HDAC6i) have been developed till date, only two ACY1215 (Ricolinostat) and ACY241 (Citarinostat) are in the clinical trials. Much work is still needed to pinpoint strictly selective as well as potent HDAC6i. Considering the recent crystal structure development of HDAC6, novel HDAC6i of significant therapeutic value can be designed. Notably, the canonical pharmacophore features of HDAC6i consist of a zinc binding group (ZBG), a linker function and a cap group. Significant modifications of cap function may lead to better selectivity of the inhibitors. This review details the study about the structural biology of HDAC6, its physiological and pathological role in several disease states and the detailed structure-activity relationships (SARs) of the known HDAC6i. This detailed review will provide key insights to design novel and highly effective HDAC6i in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yuan, Y., Peng, Q., & Gurunathan, S. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s136142 · Cited by 53
RetractedJenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Kornberg, R. D. (1974) · Science · doi:10.1126/science.184.4139.868 · Cited by 2,650
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Guo, J., Huang, F., Liu, J., Chen, Y., Wang, W., Cao, B., Zou, Z., Liu, S., Pan, J., Bao, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21230 · Cited by 2,148
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
HEF1-Dependent Aurora A Activation Induces Disassembly of the Primary Cilium
Pugacheva, E. N., Jablonski, S. A., Hartman, T. R., Henske, E. P., & Golemis, E. A. (2007) · Cell · doi:10.1016/j.cell.2007.04.035 · Cited by 890
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801
Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelières, F. P., King, S. J., Humbert, S., & Saudou, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0037-07.2007 · Cited by 792
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
Zhang, X., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J., Olashaw, N., Parsons, J. T., Yang, X.-J., Dent, S. R., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.033 · Cited by 722
HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.
Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508786200 · Cited by 719
Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
The Human Histone Deacetylase Family
Gray, S. G., & Ekström, T. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5080 · Cited by 546
Yang, W.-M., Inouye, C., Zeng, Y., Bearss, D., & Seto, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.12845 · Cited by 546
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Hai, Y., & Christianson, D. W. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2134 · Cited by 521
Lee, J.-Y., Nagano, Y., Taylor, J. P., Lim, K. L., & Yao, T.-P. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201001039 · Cited by 520
A short guide to histone deacetylases including recent progress on class II enzymes
Park, S.-Y., & Kim, J.-S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0382-4 · Cited by 509
Direct visualization of current-induced spin accumulation in topological insulators
Liu, Y., Besbas, J., Wang, Y., He, P., Chen, M., Zhu, D., Wu, Y., Lee, J. M., Wang, L., Moon, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04939-6 · Cited by 497
d'Ydewalle, C., Krishnan, J., Chiheb, D. M., Van Damme, P., Irobi, J., Kozikowski, A. P., Berghe, P. V., Timmerman, V., Robberecht, W., & Van Den Bosch, L. (2011) · Nature Medicine · doi:10.1038/nm.2396 · Cited by 454
Yang, W.-M., Yao, Y.-L., Sun, J.-M., Davie, J. R., & Seto, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28001 · Cited by 438
Kao, H.-Y., Downes, M., Ordentlich, P., & Evans, R. M. (2000) · Genes & Development · doi:10.1101/gad.14.1.55 · Cited by 424
Histone acetyltransferases: function, structure, and catalysis
Marmorstein, R., & Roth, S. Y. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00173-8 · Cited by 401
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination
Boyault, C., Sadoul, K., Pabion, M., & Khochbin, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210614 · Cited by 397
Histone deacetylase 6 interacts with the microtubule‐associated protein tau
Ding, H., Dolan, P. J., & Johnson, G. V. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05564.x · Cited by 387
Ding, W.-X., & Yin, X.-M. (2008) · Autophagy · doi:10.4161/auto.5190 · Cited by 383
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates
Boyault, C., Zhang, Y., Fritah, S., Caron, C., Gilquin, B., Kwon, S. H., Garrido, C., Yao, T.-P., Vourc’h, C., Matthias, P., et al. (2007) · Genes & Development · doi:10.1101/gad.436407 · Cited by 368
Lee, H.-Z., Kwitkowski, V. E., Del Valle, P. L., Ricci, M. S., Saber, H., Habtemariam, B. A., Bullock, J., Bloomquist, E., Li Shen, Y., Chen, X.-H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3119 · Cited by 357
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease
Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schlüter, O. M., Bradke, F., Lu, J., & Fischer, A. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201923 · Cited by 342
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes
Li, Y., Shin, D., & Kwon, S. H. (2013) · The FEBS Journal · doi:10.1111/febs.12079 · Cited by 341
Olzmann, J. A., Li, L., Chudaev, M. V., Chen, J., Perez, F. A., Palmiter, R. D., & Chin, L.-S. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611128 · Cited by 339
Histone deacetylase 6 in cancer
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 326
Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter
Westendorf, J. J., Zaidi, S. K., Cascino, J. E., Kahler, R., van Wijnen, A. J., Lian, J. B., Yoshida, M., Stein, G. S., & Li, X. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7982-7992.2002 · Cited by 324
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., & Marks, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803749105 · Cited by 321
Epigenetics—An Epicenter of Gene Regulation: Histones and Histone‐Modifying Enzymes
Biel, M., Wascholowski, V., & Giannis, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461346 · Cited by 316
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
Miyake, Y., Keusch, J. J., Wang, L., Saito, M., Hess, D., Wang, X., Melancon, B. J., Helquist, P., Gut, H., & Matthias, P. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2140 · Cited by 315
Shukla, S., & Tekwani, B. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00537 · Cited by 314
Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Sung, C.-M., Liu, R., & Winkler, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908988199 · Cited by 309
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions
Tran, A. D.-A., Marmo, T. P., Salam, A. A., Che, S., Finkelstein, E., Kabarriti, R., Xenias, H. S., Mazitschek, R., Hubbert, C., Kawaguchi, Y., et al. (2007) · Journal of Cell Science · doi:10.1242/jcs.03431 · Cited by 281
HDAC6 Regulates Mitochondrial Transport in Hippocampal Neurons
Chen, S., Owens, G. C., Makarenkova, H., & Edelman, D. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010848 · Cited by 270
Saji, S., Kawakami, M., Hayashi, S.-I., Yoshida, N., Hirose, M., Horiguchi, S.-I., Itoh, A., Funata, N., Schreiber, S. L., Yoshida, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208646 · Cited by 258
Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253
Hook, S. S., Orian, A., Cowley, S. M., & Eisenman, R. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172511699 · Cited by 224
Ouyang, H., Ali, Y. O., Ravichandran, M., Dong, A., Qiu, W., MacKenzie, F., Dhe-Paganon, S., Arrowsmith, C. H., & Zhai, R. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273730 · Cited by 221
Histone Deacetylase 6 in Health and Disease
Seidel, C., Schnekenburger, M., Dicato, M., & Diederich, M. (2015) · Epigenomics · doi:10.2217/epi.14.69 · Cited by 217
Wang, D.-F., Helquist, P., Wiech, N. L., & Wiest, O. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0505011 · Cited by 208
Yee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 203
Haggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A., & Schreiber, S. L. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00095-4 · Cited by 201
Bergman, J. A., Woan, K., Perez-Villarroel, P., Villagra, A., Sotomayor, E. M., & Kozikowski, A. P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301098e · Cited by 195
Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase
Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C., & Evans, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108931200 · Cited by 193
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718823114 · Cited by 190
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma
Sakuma, T., Uzawa, K., Onda, T., Shiiba, M., Yokoe, H., Shibahara, T., & Tanzawa, H. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.117 · Cited by 185
Essential role of HDAC6 in the regulation of PD‐L1 in melanoma
Lienlaf, M., Perez-Villarroel, P., Knox, T., Pabon, M., Sahakian, E., Powers, J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 170
Jochems, J., Boulden, J., Lee, B. G., Blendy, J. A., Jarpe, M., Mazitschek, R., Van Duzer, J. H., Jones, S., & Berton, O. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.207 · Cited by 166
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
Lu, X., Ning, Z., Li, Z., Cao, H., & Wang, X. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01024 · Cited by 166
Genetic syndromes caused by mutations in epigenetic genes
Berdasco, M., & Esteller, M. (2013) · Human Genetics · doi:10.1007/s00439-013-1271-x · Cited by 163
Role of the Tetradecapeptide Repeat Domain of Human Histone Deacetylase 6 in Cytoplasmic Retention
Bertos, N. R., Gilquin, B., Chan, G. K. T., Yen, T. J., Khochbin, S., & Yang, X.-J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408583200 · Cited by 160
HDAC6 a new cellular stress surveillance factor
Matthias, P., Yoshida, M., & Khochbin, S. (2008) · Cell Cycle · doi:10.4161/cc.7.1.5186 · Cited by 160
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma.
Louder, A. M., Singh, A., Saverno, K. R., Cappelleri, J. C., Aten, A. J., Koenig, A. S., & Pasquale, M. K. (2016) · Europe PMC (PubMed Central) · Cited by 155
Recent advances in the discovery of potent and selective HDAC6 inhibitors
Wang, X.-X., Wan, R.-Z., & Liu, Z.-P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.040 · Cited by 152
Lu, X., Cao, X., Zhu, Y., Wu, Z., Zhuang, X., Shao, M., Xu, Q., Zhou, Y., Ji, H., Lu, Q.-R., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0428-x · Cited by 151
Characterization of the two catalytic domains in histone deacetylase 6
Zou, H., Wu, Y., Navre, M., & Sang, B. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.144 · Cited by 148
Selenica, M. B., Benner, L., Housley, S. B., Manchec, B., Lee, D. C., Nash, K. R., Kalin, J. H., Bergman, J. A., Kozikowski, A. P., Gordon, M. N., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt241 · Cited by 148
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
Iyer, S. P., & Foss, F. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0043 · Cited by 146
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
Huang, P., Almeciga-Pinto, I., Jarpe, M. B., van Duzer, J. H., Mazitschek, R., Yang, M., Jones, S. S., & Quayle, S. N. (2016) · Oncotarget · doi:10.18632/oncotarget.13738 · Cited by 143
Development of a histone deacetylase 6 inhibitor and its biological effects
Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M. L., Kim, N., Ham, W.-S., Breslow, R., & Marks, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313893110 · Cited by 141
Woan, K. V., Lienlaf, M., Perez-Villarroel, P., Lee, C., Cheng, F., Knox, T. J., Woods, D. M., Barrios, K., Powers, J. J., Sahakian, E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.002 · Cited by 141
Novotny‐Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0689 · Cited by 141
Drugging the HDAC6–HSP90 interplay in malignant cells
Krämer, O. H., Mahboobi, S., & Sellmer, A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.001 · Cited by 138
Wagner, F. F., Olson, D. E., Gale, J. P., Kaya, T., Weïwer, M., Aidoud, N., Thomas, M., Davoine, E. L., Lemercier, B. C., Zhang, Y., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301355j · Cited by 129
A novel GRK2/HDAC6 interaction modulates cell spreading and motility
Lafarga, V., Aymerich, I., Tapia, O., Mayor, F., & Penela, P. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.466 · Cited by 128
The Role of HDAC6 in Alzheimer's Disease
Zhang, L., Sheng, S., & Qin, C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120727 · Cited by 127
Wang, Z., Leng, Y., Wang, J., Liao, H.-M., Bergman, J. A., Leeds, P. R., Kozikowski, A. P., & Chuang, D. (2016) · Scientific Reports · doi:10.1038/srep19626 · Cited by 127
Brindisi, M., Saraswati, A. P., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00924 · Cited by 125
Vishwakarma, S., Iyer, L. R., Muley, M. M., Singh, P., Shastry, A., Saxena, A., Kulathingal, J., Vijaykanth, G., Raghul, J., Rajesh, N., et al. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.03.016 · Cited by 124
Deacetylation of Miro1 by HDAC6 blocks mitochondrial transport and mediates axon growth inhibition
Kalinski, A. L., Kar, A. N., Craver, J., Tosolini, A. P., Sleigh, J. N., Lee, S. J., Hawthorne, A., Brito-Vargas, P., Miller-Randolph, S., Passino, R., et al. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201702187 · Cited by 123
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Self-citationBobrowska, A., Paganetti, P., Matthias, P., & Bates, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020696 · Cited by 121
Zhou, X., Richon, V. M., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1056 · Cited by 120
Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors
Estiu, G. L., Greenberg, E. F., Harrison, C. B., Kwiatkowski, N. P., Mazitschek, R., Bradner, J. E., & Wiest, O. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015254 · Cited by 119
Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway
Saito, S., Zhuang, Y., Shan, B., Danchuk, S. D., Luo, F., Korfei, M., Günther, A., & Lasky, J. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186615 · Cited by 119
Senger, J., Melesina, J., Marek, M., Romier, C., Oehme, I., Witt, O., Sippl, W., & Jung, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01493 · Cited by 116
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease
Benoy, V., Helleputte, L. V., Prior, R. C., d’Ydewalle, C. V. O., Haeck, W., Geens, N., Scheveneels, W., Schevenels, B., Cader, M. Z., Talbot, K., et al. (2017) · Brain · doi:10.1093/brain/awx375 · Cited by 116
The role of epigenetics in personalized medicine: challenges and opportunities
Rasool, M., Malik, A., Naseer, M. I., Manan, A., Ansari, S. A., Begum, I., Qazi, M. H., Pushparaj, P. N., Abuzenadah, A. M., Al-Qahtani, M. H., et al. (2015) · BMC Medical Genomics · doi:10.1186/1755-8794-8-s1-s5 · Cited by 115
Mo, Z., Zhao, X., Liu, H., Hu, Q., Chen, X., Pham, J., Wei, N., Liu, Z., Zhou, J., Burgess, R. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03461-z · Cited by 114
Yu, C., Chang, P., Hsin, L., & Chern, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400564j · Cited by 113
Williams, K. A., Zhang, M., Xiang, S., Chen, H., Wu, J.-Y., Zhang, S., Ryan, M. B., Cox, A. D., Der, C. J., Fang, B., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.472506 · Cited by 112
Porter, N. J., Osko, J. D., Diedrich, D., Kurz, T., Hooker, J. M., Hansen, F. K., & Christianson, D. W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01013 · Cited by 111
Mishima, Y. M., Santo, L., Eda, H., Cirstea, D. D., Nemani, N., Yee, A. J., O’Donnell, E., Selig, M. K., Quayle, S. N., Arastu‐Kapur, S., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13315 · Cited by 107
Kerr, E. M., Holohan, C., McLaughlin, K. M., Majkut, J., Dolan, S., Redmond, K. M., Riley, J. S., McLaughlin, K. M., Stasik, I., Crudden, M. T. C. M., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.8 · Cited by 106
Fan, S.-J., Huang, F.-I., Liou, J., & Yang, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0688-5 · Cited by 105
Vögerl, K., Ong, N., Senger, J., Herp, D., Schmidtkunz, K., Marek, M., Müller, M., Bartel, K., Shaik, T. B., Porter, N. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01090 · Cited by 104
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
Barbarotta, L., & Kristen Hurley, R. (2015) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2015.6.1.3 · Cited by 101
HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity
Ding, G., Liu, H., Huang, Q., Liang, H., Ding, Z.-H., Liao, Z., & Huang, G. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.02.001 · Cited by 100
Selective vulnerability in α-synucleinopathies
Alegre‐Abarrategui, J., Brimblecombe, K. R., Roberts, R. F., Velentza‐Almpani, E., Tilley, B. S., Bengoa‐Vergniory, N., & Proukakis, C. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02010-2 · Cited by 97
The Acetylation of Lysine-376 of G3BP1 Regulates RNA Binding and Stress Granule Dynamics
Gál, J., Chen, J., Na, D.-Y., Tichacek, L., Barnett, K. R., & Zhu, H. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00052-19 · Cited by 97
Shen, S., Svoboda, M., Zhang, G., Cavasin, M. A., Motlova, L., McKinsey, T. A., Eubanks, J. H., Bařinka, C., & Kozikowski, A. P. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00560 · Cited by 94
Benoy, V., Berghe, P. V., Jarpe, M. B., Damme, P. V., Robberecht, W., & Bosch, L. V. D. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0501-z · Cited by 91
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin
Chen, W. (2011) · Oncology Reports · doi:10.3892/or.2011.1553 · Cited by 89
Lee, H., Nepali, K., Huang, F.-I., Chang, C. S., Lai, M.-J., Li, Y.-H., Huang, H.-L., Yang, C., & Liou, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01404 · Cited by 89
HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination
Strebl, M. G., Campbell, A. J., Zhao, W., Schroeder, F. A., Riley, M. M., Chindavong, P. S., Morin, T., Haggarty, S. J., Wagner, F. F., Ritter, T., et al. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00274 · Cited by 87
Adhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 87
Self-citationCao, J., Lv, W., Wang, L., Xu, J., Yuan, P., Huang, S., He, Z., & Hu, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0788-2 · Cited by 86
Shen, S., Hadley, M. M., Ustinova, K., Pavlíček, J., Knox, T. J., Noonepalle, S. K. R., Tavares, M. T., Zimprich, C., Zhang, G., Robers, M. B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00946 · Cited by 86
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
Cosenza, M., & Pozzi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082337 · Cited by 85
Choi, S. Y., Ryu, Y., Kee, H. J., Cho, S., Kim, G. R., Cho, J. Y., Kim, H.-S., Kim, I., & Jeong, M. H. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.04.006 · Cited by 84
Liu, J.-R., Yu, C., Hung, P.-Y., Hsin, L., & Chern, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.023 · Cited by 84
Osko, J. D., & Christianson, D. W. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00934 · Cited by 83
Chang, Y.-W., Tseng, C.-F., Wang, M.-Y., Chang, W.-C., Lee, C.-C., Chen, L.-T., Hung, M.-C., & Su, J.-L. (2016) · Oncogene · doi:10.1038/onc.2015.214 · Cited by 82
Shen, S., Benoy, V., Bergman, J. A., Kalin, J. H., Damião, M. C. F. C. B., Vistoli, G., Haeck, W., Bosch, L. V. D., & Kozikowski, A. P. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00286 · Cited by 81
Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor
Bhatia, S., Krieger, V., Groll, M., Osko, J. D., Reßing, N., Ahlert, H., Borkhardt, A., Kurz, T., Christianson, D. W., Hauer, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01487 · Cited by 79
Lee, H., Fan, S.-J., Huang, F.-I., Chao, H.-Y., Hsu, K., Lin, T. E., Yeh, T., Lai, M.-J., Li, Y.-H., Huang, H.-L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00151 · Cited by 77
Ma, J., Huo, X., Jarpe, M. B., Kavelaars, A., & Heijnen, C. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0604-3 · Cited by 77
Acetylation modification regulates GRP78 secretion in colon cancer cells
Li, Z., Zhuang, M., Zhang, L., Zheng, X., Yang, P., & Li, Z. (2016) · Scientific Reports · doi:10.1038/srep30406 · Cited by 76
Histone Deacetylase 6 (HDAC6) Deacetylates Survivin for Its Nuclear Export in Breast Cancer
Riolo, M., Cooper, Z. A., Holloway, M. P., Cheng, Y., Bianchi, C. F., Yakirevich, E., Ma, L., Chin, Y. E., & Altura, R. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308791 · Cited by 75
Das, C., & Kundu, T. K. (2005) · IUBMB Life · doi:10.1080/15216540500090629 · Cited by 73
NF-κB inhibits transcription of the H+-K+-ATPase α2-subunit gene: role of histone deacetylases
Zhang, W., & Kone, B. C. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00156.2002 · Cited by 73
Mackwitz, M. K. W., Hamacher, A., Osko, J. D., Held, J., Schöler, A., Christianson, D. W., Kassack, M. U., & Hansen, F. K. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b01118 · Cited by 69
de Freitas, R. F., Harding, R., Franzoni, I., Ravichandran, M., Mann, M. K., Ouyang, H., Lautens, M., Santhakumar, V., Arrowsmith, C. H., & Schapira, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00258 · Cited by 68
HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice
Picci, C., Wong, V. S. C., Costa, C. J., McKinnon, M. C., Goldberg, D. C., Swift, M. L., Alam, N. M., Prusky, G. T., Shen, S., Kozikowski, A. P., et al. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113281 · Cited by 68
Xu, X., Kozikowski, A. P., & Pozzo‐Miller, L. D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00068 · Cited by 66
Trivedi, P., Adhikari, N., Amin, S. A., Jha, T., & Ghosh, B. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.030 · Cited by 66
Self-citationFunction of Histone Deacetylase 6 as a Cofactor of Nuclear Receptor Coregulator LCoR
Palijan, A., Fernandes, I., Bastien, Y., Tang, L., Verway, M., Kourelis, M., Tavera-Mendoza, L. E., Li, Z., Bourdeau, V., Mader, S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045526 · Cited by 65
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6
Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00367 · Cited by 64
MCPIP1 reduces HBV-RNA by targeting its epsilon structure
Li, Y., Que, L., Fukano, K., Koura, M., KITAMURA, K., Zheng, X., Kato, T., Aly, H. H., Watashi, K., Tsukuda, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77166-z · Cited by 64
Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome
den Veyver, I. B. V., & Zoghbi, H. Y. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00376-x · Cited by 63
Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors
Tang, G., Wong, J. C., Zhang, W., Wang, Z., Zhang, N., Peng, Z., Zhang, Z., Rong, Y., Li, S., Zhang, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008962 · Cited by 62
Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity
Han, Y., Jeong, H. M., Jin, Y.-H., Kim, Y.-J., Jeong, H. G., Yeo, C., & Lee, K.-Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.147 · Cited by 61
Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6
Lissanu Deribe, Y., Wild, P., Chandrashaker, A., Curak, J., Schmidt, M. H. H., Kalaidzidis, Y., Milutinovic, N., Kratchmarova, I., Buerkle, L., Fetchko, M. J., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000576 · Cited by 60
Vergani, B., Sandrone, G., Marchini, M., Ripamonti, C., Cellupica, E., Galbiati, E., Caprini, G., Pavich, G., Porro, G., Rocchio, I., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01194 · Cited by 60
Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity
Francelle, L., Outeiro, T. F., & Rappold, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-62678-5 · Cited by 60
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
Putcha, P., Yu, J., Barrueco, R. R., Saucedo-Cuevas, L. P., Villagrasa, P., Murga-Penas, E., Quayle, S. N., Yang, M., Castro, V., Llobet‐Navàs, D., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0658-0 · Cited by 58
Osko, J. D., Porter, N. J., Poli, A. N. R., Xiao, Y., Rokka, J., Jung, M., Hooker, J. M., Salvino, J. M., & Christianson, D. W. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01540 · Cited by 58
HDAC6 as a target for antileukemic drugs in acute myeloid leukemia
Hackanson, B. W., Rimmele, D. L., Benkißer-Petersen, M., Abdelkarim, M., Fliegauf, M., Jung, M., & Lübbert, M. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.026 · Cited by 57
Yu, C., Hung, P.-Y., Yang, H.-T., Ho, Y.-H., Lai, H.-Y., Cheng, Y., & Chern, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01590 · Cited by 56
Osko, J. D., & Christianson, D. W. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127023 · Cited by 56
Gold, W. A., Lacina, T. A., Cantrill, L. C., & Christodoulou, J. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1202-x · Cited by 55
Yang, C., Liu, Y.-P., Dai, H.-Y., Shiue, Y., Tsai, C.-J., Huang, M., & Yeh, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4749 · Cited by 54
Cosenza, M., Civallero, M., Marcheselli, L., Sacchi, S., & Pozzi, S. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1364-4 · Cited by 54
Chen, X., Chen, X., Steimbach, R. R., Wu, T., Li, H., Dan, W., Shi, P., Cao, C., Li, D., Miller, A. K., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111950 · Cited by 54
HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT
Rossaert, E., & Bosch, L. V. D. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146692 · Cited by 54
Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors
Diedrich, D., Hamacher, A., Gertzen, C. G. W., Avelar, L. A. A., Reiß, G. J., Kurz, T., Gohlke, H., Kassack, M. U., & Hansen, F. K. (2016) · Chemical Communications · doi:10.1039/c5cc10301k · Cited by 53
Ojha, R., Nepali, K., Chen, C., Chuang, K.-H., Wu, T.-Y., Lin, T. E., Hsu, K., Chao, M., Lai, M.-J., Lin, M.-H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112086 · Cited by 52
Zheng, Y., Yang, X., Wang, C., Zhang, S., Wang, Z., Li, M., Wang, X., Wang, X., & Yang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-60271-4 · Cited by 50
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
North, B. J., Almeciga-Pinto, I., Tamang, D., Yang, M., Jones, S. S., & Quayle, S. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173507 · Cited by 49
Wu, J.-Y., Xiang, S., Zhang, M., Fang, B., Huang, H., Kwon, O. K., Zhao, Y., Yang, Z., Bai, W., Bepler, G., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.795955 · Cited by 47
Trivedi, P., Adhikari, N., Amin, S. A., Bobde, Y., Routholla, G., Jha, T., & Ghosh, B. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105046 · Cited by 47
Self-citationDu, Y., Wang, F., Zou, J., Le, W., Dong, Q., Wang, Z., Shen, F., Yu, L., & Li, Y. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.029 · Cited by 46
A novel class of anthraquinone-based HDAC6 inhibitors
Song, Y., Lim, J., & Seo, Y. H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.056 · Cited by 45
Design and Synthesis of Orally Bioavailable Aminopyrrolidinone Histone Deacetylase 6 Inhibitors
Lin, X., Chen, W.-M., Qiu, Z., Guo, L., Zhu, W., Li, W., Wang, Z., Zhang, W., Zhang, Z., Rong, Y., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm502011f · Cited by 44
Hsieh, Y.-L., Tu, H., Pan, S., Liou, J., & Yang, C. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.03.003 · Cited by 44
Segretti, M. C. F., Vallerini, G. P., Brochier, C., Langley, B. C., Wang, L., Hancock, W. W., & Kozikowski, A. P. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00303 · Cited by 42
Harding, R., de Freitas, R. F., Collins, P. M., Franzoni, I., Ravichandran, M., Ouyang, H., Juárez‐Ornelas, K. A., Lautens, M., Schapira, M., von Delft, F., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00933 · Cited by 41
HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
Losson, H., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2020) · Cancers · doi:10.3390/cancers12020318 · Cited by 40
Vreese, R. D., Galle, L. M., Depetter, Y., Franceus, J., Desmet, T., Hecke, K. V., Benoy, V., Bosch, L. V. D., & D’hooghe, M. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604167 · Cited by 39
Lv, W., Zhang, G., Bařinka, C., Eubanks, J. H., & Kozikowski, A. P. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00012 · Cited by 39
Creation of a histone deacetylase 6 inhibitor and its biological effects
Lee, J., Yao, Y., Mahendran, A., Ngo, L., Venta-Perez, G., Choy, M. L., Breslow, R., & Marks, P. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515882112 · Cited by 38
Vreese, R. D., Verhaeghe, T., Desmet, T., & D’hooghe, M. (2013) · Chemical Communications · doi:10.1039/c3cc41422a · Cited by 38
Ghosh, B., Zhao, W., Reis, S. A., Patnaik, D., Fass, D. M., Tsai, L., Mazitschek, R., & Haggarty, S. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.022 · Cited by 38
Self-citationDesign and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors
Morgen, M., Steimbach, R. R., Géraldy, M. N. E., Hellweg, L., Sehr, P. A., Ridinger, J., Witt, O., Oehme, I., Herbst‐Gervasoni, C. J., Osko, J. D., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000149 · Cited by 35
Roberds, S. L., Filippov, I., Alexandrov, V., Hanania, T., & Brunner, D. (2011) · Frontiers in Neuroscience · doi:10.3389/fnins.2011.00103 · Cited by 34
aPKC Phosphorylation of HDAC6 Results in Increased Deacetylation Activity
Du, Y., Seibenhener, M. L., Yan, J., Jiang, J., & Wooten, M. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123191 · Cited by 34
Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells
Kamemura, K., Ito, A., Shimazu, T., Matsuyama, A., Maeda, S., Yao, T., Horinouchi, S., Khochbin, S., & Yoshida, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.092 · Cited by 33
Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors
Vreese, R. D., Steen, N. V., Verhaeghe, T., Desmet, T., Bougarne, N., Bosscher, K. D., Benoy, V., Haeck, W., Bosch, L. V. D., & D’hooghe, M. (2015) · Chemical Communications · doi:10.1039/c5cc03295d · Cited by 33
Porter, N. J., Shen, S., Bařinka, C., Kozikowski, A. P., & Christianson, D. W. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00487 · Cited by 33
LoPresti, P. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00519 · Cited by 33
Lim, J. A., & Juhnn, Y. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.98 · Cited by 30
Sun, X., Xie, Y., Sun, X., et al. (2019) · Bioscience Reports · doi:10.1042/bsr20181916 · Cited by 29
Tao, L., Hou, X., Zhou, Y., Yang, X., & Fang, H. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00084 · Cited by 29
Kozlov, M. V., Kleymenova, A. A., Konduktorov, K. A., Malikova, A. Z., & Kochetkov, S. N. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914070050 · Cited by 28
Wang, Z., Hu, P., Tang, F., & Xie, C. (2016) · Medical Oncology · doi:10.1007/s12032-016-0765-5 · Cited by 28
HDAC6 interacts with PTPN1 to enhance melanoma cells progression
Liu, J., Luan, W., Zhang, Y., Gu, J., Shi, Y., Yang, Y., Feng, Z., & Qi, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.145 · Cited by 28
Designing potential HDAC3 inhibitors to improve memory and learning
Amin, S. A., Adhikari, N., Jha, T., & Ghosh, B. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1477625 · Cited by 28
Self-citationVreese, R. D., Depetter, Y., Verhaeghe, T., Desmet, T., Benoy, V., Haeck, W., Bosch, L. V. D., & D’hooghe, M. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02625c · Cited by 26
Hamoud, M. M. S., Pulya, S., Osman, N. A., Bobde, Y., Hassan, A. E. A., Abdel‐Fattah, H. A., Ghosh, B., & Ghanim, A. M. (2020) · New Journal of Chemistry · doi:10.1039/d0nj01274b · Cited by 25
Self-citationYin, Z., Xu, W., Xu, H., Zheng, J., & Gu, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9504 · Cited by 23
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia
Maharaj, K. K., Powers, J. J., Achille, A. N., Deng, S., Fonseca, R., Pabón-Saldaña, M., Quayle, S. N., Jones, S. S., Villagra, A., Sotomayor, E. M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020065 · Cited by 23
Yoo, J., Kim, S., Son, D., Seo, H., Baek, S. Y., Maeng, C.-Y., Lee, C., Kim, I. S., Jung, Y. H., Lee, S., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.046 · Cited by 21
Niesvizky, R., Richardson, P. G. G., Yee, A. J., Nooka, A. K., Raab, M. S., Shain, K. H., Gabrail, N. Y., Matous, J., Agarwal, A. B., Hoffman, J. E., et al. (2016) · Blood · doi:10.1182/blood.v128.22.3307.3307 · Cited by 21
Nam, G., Jung, J. M., Park, H., Baek, S. Y., Baek, K. S., Mok, H. Y., Kim, D. E., & Jung, Y. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.06.036 · Cited by 21
Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
Sharma, C., Oh, Y. J., Park, B., Lee, S., Jeong, C., Lee, S. K., Seo, J. H., & Seo, Y. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246213 · Cited by 21
Liu, Y., Li, L., & Min, J. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2158 · Cited by 20
HDAC6 and Miro1: Another interaction causing trouble in neurons
Bosch, L. V. D. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201904016 · Cited by 12
Cited by
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77
Routholla, G., Pulya, S., Patel, T., Abdul Amin, S., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105050 · Cited by 39
Self-citationWang, X.-X., Xie, F., Jia, C.-C., Yan, N., Zeng, Y.-L., Wu, J.-D., & Liu, Z.-P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113821 · Cited by 23
Metadata
- Authors
- Pulya, S., Amin, S. A., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 163
- Pages
- 105274
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W3097213302
- Cited by
- 253
- References
- 200
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.